van der Palen, Job
Thomas, Mike
Chrystyn, Henry
Sharma, Raj K
van der Valk, Paul DLPM
Goosens, Martijn
Wilkinson, Tom
Stonham, Carol
Chauhan, Anoop J
Imber, Varsha
Zhu, Chang-Qing
Svedsater, Henrik
Barnes, Neil C
Article History
Received: 19 May 2016
Revised: 20 September 2016
Accepted: 25 September 2016
First Online: 24 November 2016
Competing interests
: JvdP has no shares in any pharmaceutical companies. He has received sponsorship to carry out studies and has participated in Advisory Boards from several pharmaceutical companies that market inhaled products. These include Almirall, Boehringer Ingelheim (BI), GlaxoSmithKline (GSK), Mundipharma and Teva. Neither MT nor any member of his close family has any shares in pharmaceutical companies. In the past 3 years, he has received speaker’s honoraria for speaking at sponsored meetings or satellite symposia at conferences from the following companies marketing respiratory and allergy products: Aerocrine, AstraZeneca, BI, GSK, Teva and Novartis. He has received honoraria for attending advisory panels with: Aerocrine, Almirall, AstraZeneca, BI, Chiesi, GSK, MSD, Novartis, Pfizer, Roche and Sandoz. He has received sponsorship to attend international scientific meetings from: GSK and AstraZeneca. He has received funding for research projects from GSK. He is a member of the BTS SIGN Asthma guideline group and the NICE Asthma guideline group. HC has no shares in any pharmaceutical companies. He has received sponsorship from several pharmaceutical companies that market inhaled products to carry out: clinical studies, Board Membership, consultant agreements and honoraria for presentations. These include Almirall, AstraZeneca, BI, Chiesi, GSK, Innovata Biomed, Meda, Napp Pharmaceuticals, Mundipharma, NorPharma, Norvartis, Orion, Sanofi, Teva, Truddell Medical International, UCB and Zentiva. Research sponsorship has also been received from grant awarding bodies (EPSRC and MRC). He is the owner of Inhalation Consultancy Ltd and a director of Talmedica Ltd. TW has received research funding and consultancy fees from GSK, AstraZeneca and BI. He is a Director of my mHealth Ltd. CS has no shares in any pharmaceutical companies. She has received consultant agreements and honoraria for presentations from several pharmaceutical companies that market inhaled medication. These include AstraZeneca, Chiesi, GSK, Napp Pharmaceuticals and Teva. NB, RS, VI, HS and C-QZ are employees of GSK and hold stock in GSK. The remaining authors declare no conflict of interest.